BPG is committed to discovery and dissemination of knowledge
Articles in Press
3/24/2023 6:27:41 AM | Browse: 49 | Download: 9
Publication Name World Journal of Hepatology
Manuscript ID 80145
Country China
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Recent advances in recurrent hepatocellular carcinoma therapy
Manuscript Source Invited Manuscript
All Author List Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, Tong-Wang Yang and De-Xi Chen
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 82073676
Chinesisch-Deutsches Forschungsprojekt in Sonderprogramm zu COVID-19 C-0012
Key Programs of Beijing Municipal Education Commission of China KZ202010025037
Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes Jing 2019-6
Fourth Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes Jing 2021-10
Corresponding Author De-Xi Chen, PhD, Professor, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, No. 8 Youanmenwai, Youanmen Street, Fengtai District, Beijing 100069, China. dexichen@ccmu.edu.cn
Key Words Recurrent hepatocellular carcinoma; Liver transplantation; Therapy; Immunotherapy; Neoadjuvant and adjuvant therapy
Core Tip Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, and up to 50%-70% of individuals may experience a relapse of the illness in the liver after 5 years. This review will provide novel approaches to improve the prognosis of patients with recurring HCC with the apparent lack of data to guide the clinical treatment. Neoadjuvant and/or adjuvant therapy methods potentially elevate the opportunity of cure in refractory patients with recurrent HCC and contribute to a better long-term prognosis.
Citation Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent hepatocellular carcinoma therapy. World J Hepatol 2023; 15(4): 460-476
Received
2022-09-19 00:10
Peer-Review Started
2022-09-19 00:12
To Make the First Decision
Return for Revision
2022-12-01 04:53
Revised
2022-12-20 06:34
Second Decision
2023-03-24 02:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-03-24 06:27
Articles in Press
2023-03-24 06:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-03-16 02:57
Typeset the Manuscript
2023-03-27 09:33
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com